#LCSM Chat Topic 3/22: Slicing the Pie–How Can Lung Cancer Patient Groups, Clinicians, and Researchers Best Work Together?

Lung cancer management has shifted from a broadly defined process to one increasingly recognized as narrow subgroups that have distinct patterns of cancer biology and optimal treatments.  The first patient group to splinter into a separate branch of management was the approximately 10% of people with EGFR mutation-positive NSCLC, and the treatment options for them continue to become deeper and more complex as we gain more active agents and struggle with enviable problems like the best sequencing and protection of the brain against metastatic spread. Other “driver mutations” such as ALK and… Read More

#LCSM Chat topic 3/8/2018: Cancer advocacy 101–patients & conferences

As cancer patients and caregivers transform into active cancer advocates, they may think about attending medical conferences.  On March 8, at 8 pm Eastern Time (5 pm PST), #LCSM Chat will discuss various aspects of cancer advocate participation in medical conferences. Some reasons for cancer advocates to attend medical conferences are to: Learn more about cancer and treatment options for cancer Get details about new research Meet the top doctors who treat their type of cancer Support an advocacy organization’s outreach booth Network with other advocates, as well as clinicians and researchers… Read More

#LCSM Chat Topic 2/8/18: Right to Try Laws and CIMAVax

  “Right to Try” laws for people with a terminal illness have been a longstanding issue and are currently on the books in 38 states. The lack of a federal law supporting this concept was touched upon in President Trump’s State of the Union address last week. On its face, offering liberal options that permit these patients to try any still investigational agent that has completed phase I testing seems like a benefit to patients who may be desperate for options. A couple of arguments in favor of it are available here:… Read More